Does Rallies show Form 4 insider transactions for CLOV?

Yes. Rallies tracks CLOV insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CLOV research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CLOV. It does not provide personalized investment advice.

CLOV (Clover Health Investments, Corp) Stock Analysis - Insider Trades

Clover Health Investments, Corp (CLOV) is a publicly traded Healthcare sector company. As of May 21, 2026, CLOV trades at $3.59 with a market cap of $1.79B and a P/E ratio of 0.00. CLOV moved +2.57% today. Year to date, CLOV is +38.61%; over the trailing twelve months it is -2.71%. Its 52-week range spans $1.58 to $4.87. Analyst consensus is buy with an average price target of $2.98. Rallies surfaces CLOV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CLOV stock inside the company?

Recent CLOV insider activity includes Priest Brady Patrick sold 98.04K, Reynoso Jamie L. sold 5.83K, Priest Brady Patrick sold 175.00K, Reynoso Jamie L. sold 4.60K, and Reynoso Jamie L. sold 2.10K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CLOV Key Metrics

Key financial metrics for CLOV
Metric	Value
Price	$3.59
Market Cap	$1.79B
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$4.87
52-Week Low	$1.58
Volume	132
Avg Volume	0
Revenue (TTM)	$2.21B
Net Income	$-56.94M
Gross Margin	0.00%

Recent CLOV Insider Trades

Priest Brady Patrick sold 98.04K (~$345.10K) on May 13, 2026.
Reynoso Jamie L. sold 5.83K (~$11.14K) on Mar 18, 2026.
Priest Brady Patrick sold 175.00K (~$379.75K) on Mar 4, 2026.
Reynoso Jamie L. sold 4.60K (~$11.86K) on Jan 20, 2026.
Reynoso Jamie L. sold 2.10K (~$5.32K) on Jan 7, 2026.

Latest CLOV News

Clover Health Posts $27M Q1 Profit, 62% Revenue Growth, 51% Membership Increase — May 6, 2026
CFO Change at Clover Health: Peter Kuipers Exits March 30, Thornton Named Interim, 2026 Guidance Reconfirmed — Apr 1, 2026
Medtech Surge Fuels Clover Health in $Billions Outpatient, AI Diagnostics Shift — Mar 27, 2026
Clover Health’s AI Assistant cuts flu events 22% and projects 49% revenue growth — Mar 19, 2026
Clover Health Launches Real-Time FHIR USCDI v3 Data Exchange on Kno2 — Mar 10, 2026

CLOV Analyst Consensus

2 analysts cover CLOV: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.98.

Common questions about CLOV

Who is trading CLOV stock inside the company?: Recent CLOV insider activity includes Priest Brady Patrick sold 98.04K, Reynoso Jamie L. sold 5.83K, Priest Brady Patrick sold 175.00K, Reynoso Jamie L. sold 4.60K, and Reynoso Jamie L. sold 2.10K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CLOV?: Yes. Rallies tracks CLOV insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CLOV research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CLOV. It does not provide personalized investment advice.